AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34221476 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Auricular Acupuncture
Number of subjects: 60
Study 34221476 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Auricular Acupuncture with Counselling
Number of subjects: 60
Study 34221476 — intervention group
Group type: COMPARATOR
Intervention: Psychological Counselling
Number of subjects: 60
Study 34221476 — intervention group
Group type: COMPARATOR
Intervention: Control Group (No intervention specified)
Number of subjects: 60
Study 32271146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure aerobic exercise
Number of subjects: 45
Study 32271146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic resistance exercise
Number of subjects: 45
Study 32271146 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual treatment)
Number of subjects: 45
Study 35550356 — intervention group
Group type: EXPERIMENTAL
Intervention: r-ESWT
Number of subjects: 30
Study 35550356 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 30
Study 34086195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-DGA attendance for examination
Number of subjects: 80
Study 34086195 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-DGA attendance for examination
Number of subjects: 80
Study 34086195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-DGA attendance at emergency appointments
Number of subjects: 80
Study 34086195 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-DGA attendance at emergency appointments
Number of subjects: 80
Study 34086195 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative intervention over 24 months
Number of subjects: 80
Study 34086195 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of operative treatment post-DGA
Number of subjects: 80
Study 36304817 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-20 (1000 mg, delivering 192 mg fisetin)
Number of subjects: 15
Study 36304817 — intervention group
Group type: COMPARATOR
Intervention: UF (1000 mg)
Number of subjects: 15
Study 33025926 — intervention group
Group type: COMPARATOR
Intervention: Insulin Syringe (IS)
Number of subjects: 80
Study 33025926 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-Controlled Syringe (ACS)
Number of subjects: 80
Study 33025926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IS and ACS
Number of subjects: 80
Study 33306564 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart-pill bottle service
Number of subjects: 63
Study 33306564 — intervention group
Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 63
Study 33306564 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart-pill bottle service (after excluding 3 participants with drug-drug interactions)
Number of subjects: 63
Study 33306564 — intervention group
Group type: COMPARATOR
Intervention: Control arms (after excluding 3 participants with drug-drug interactions)
Number of subjects: 63
Study 33076932 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical risk information (risk categories of one in 40, one in 1600 and one in 3500)
Number of subjects: 2767
Study 33076932 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical risk information (highest, moderate and lowest risk)
Number of subjects: 2767
Study 33076932 — intervention group
Group type: COMPARATOR
Intervention: Positive screening result letter (control group)
Number of subjects: 2767
Study 33076932 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (numerical, categorical, control)
Number of subjects: 2767
Study 36041732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Number of subjects: 8
Study 36041732 — intervention group
Group type: COMPARATOR
Intervention: Glucose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Number of subjects: 8
Study 36041732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose and rice
Number of subjects: 8
Study 36041732 — intervention group
Group type: COMPARATOR
Intervention: Glucose and rice
Number of subjects: 8
Study 33772433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulphate (3 mL of 3.2% MgSO4 every 4 hours for 24 hours)
Number of subjects: 60
Study 33772433 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 60
Study 32591823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo+surgery
Number of subjects: 218
Study 32591823 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 218
Study 35333024 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and up to 8 individual consultations with a specialist in sexual counseling
Number of subjects: 158
Study 35333024 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study 32253548 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (TXA) administered before incision, 3, 6, 12, 18, and 24 hours later (Group D)
Number of subjects: 0
Study 32253548 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (TXA) (Group D)
Number of subjects: 0
Study 32253548 — intervention group
Group type: COMPARATOR
Intervention: No TXA (Group A)
Number of subjects: 0
Study 32253548 — intervention group
Group type: COMPARATOR
Intervention: All groups (including Group D)
Number of subjects: 0
Study 34967670 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim resistance in date rapes involving male victims
Number of subjects: 622
Study 34967670 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim gender and victim resistance
Number of subjects: 622
Study 34967670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rape type and victim gender
Number of subjects: 622
Study 33392930 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference trial (PCT)
Number of subjects: 416
Study 33392930 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially randomized patient preference trial (PRPPT)
Number of subjects: 416
Study 33392930 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 416
Study 33119884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung metastasectomy
Number of subjects: 0
Study 33119884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metastasectomy)
Number of subjects: 0
Study 32498372 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS), three times daily for six months
Number of subjects: 92
Study 32498372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 33451648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density peptide arrays screening of twelve leading vaccine candidates as overlapping 15-mer peptides.
Number of subjects: 27
Study 33451648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioinformatics approach to predict immunogenic malaria epitopes validated in the assay.
Number of subjects: 27
Study 33451648 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected peptides from the malaria proteome as a control.
Number of subjects: 27
Study 34928484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg intravenously every 2 weeks) plus Erlotinib (150 mg/day orally)
Number of subjects: 446
Study 34928484 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Erlotinib (150 mg/day orally)
Number of subjects: 446
Study 32336587 — intervention group
Group type: EXPERIMENTAL
Intervention: 20° lateral view
Number of subjects: 124
Study 32336587 — intervention group
Group type: COMPARATOR
Intervention: 0° lateral view
Number of subjects: 124
Study 36881395 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapies (GDMT)
Number of subjects: 17
Study 36881395 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker
Number of subjects: 17
Study 36881395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 34189606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Education and Prevention Program (OHEPP)
Number of subjects: 28
Study 34189606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational interventions)
Number of subjects: 28
Study 32711612 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB PC (albumin‐binding paclitaxel 130 mg/mL, D1, D; carboplatin AUC = 6, D1)
Number of subjects: 60
Study 32711612 — intervention group
Group type: COMPARATOR
Intervention: PC (paclitaxel 175 mg/mL, D1; carboplatin AUC = 6, D1)
Number of subjects: 60
Study 32711612 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB PC
Number of subjects: 60
Study 32711612 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 60
Study 35440448 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant tummy time intervention group (practice, education, WhatsApp) plus usual care
Number of subjects: 0
Study 35440448 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study 32950674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 101
Study 32950674 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid Injection (CS)
Number of subjects: 101
Study 34976652 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children – for Caregivers (ICC‐C) intervention
Number of subjects: 203
Study 34976652 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 203
Study 34448685 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised Content Knowledge (SCK) training
Number of subjects: 216
Study 34448685 — intervention group
Group type: COMPARATOR
Intervention: Common Content Knowledge (CCK) training
Number of subjects: 216
Study 34448685 — intervention group
Group type: EXPERIMENTAL
Intervention: SCK training
Number of subjects: 216
Study 33407492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting adverse outcomes including heart rate, systolic pressure, N-terminal-pro brain natriuretic peptide, and ventricle/atrial diameter ratios at 4-chamber view.
Number of subjects: 845
Study 34151667 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Pilates (n=4)
Number of subjects: 10
Study 34151667 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Pilates (n=6)
Number of subjects: 10
Study 33340400 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 40
Study 33340400 — intervention group
Group type: COMPARATOR
Intervention: Monitoring Only (MO)
Number of subjects: 40
Study 36053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 26 weeks
Number of subjects: 181
Study 36053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 9 weeks
Number of subjects: 181
Study 36053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 26 weeks
Number of subjects: 181
Study 36053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 9 weeks
Number of subjects: 181
Study 36053506 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 181
Study 33159424 — intervention group
Group type: COMPARATOR
Intervention: Belgium cohort (n=30)
Number of subjects: 121
Study 33159424 — intervention group
Group type: EXPERIMENTAL
Intervention: Guinea cohort (n=91)
Number of subjects: 121
Study 33159424 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI analysis of prospective cohort (n=30)
Number of subjects: 121
Study 35453124 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garment group (shin splints compression wrap during waking hours for 2 weeks, then during activity for 6 weeks)
Number of subjects: 0
Study 35453124 — intervention group
Group type: COMPARATOR
Intervention: Relative rest group
Number of subjects: 0
Study 34023009 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg plus topical corticosteroids
Number of subjects: 901
Study 34023009 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg plus topical corticosteroids
Number of subjects: 901
Study 34023009 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus topical corticosteroids
Number of subjects: 901
Study 35665810 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum (4 μg) with oral vitamin D
Number of subjects: 109
Study 35665810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 32791011 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet (KD) utilizing medium chained triglyceride fats during a four-month period
Number of subjects: 0
Study 32791011 — intervention group
Group type: COMPARATOR
Intervention: Institutionalized standard traditional diet
Number of subjects: 0
Study 35940560 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 3g administered intra-articular after cementation and prior to capsular closure
Number of subjects: 150
Study 35940560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 35940560 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 150
Study 35940560 — intervention group
Group type: COMPARATOR
Intervention: Topical tranexamic acid (TXA) and Placebo
Number of subjects: 150
Study 33844449 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg once daily)
Number of subjects: 304
Study 33844449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 33844449 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 304
Study 34323666 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0
Study 35126208 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH) service in Zurich providing targeted, individual and flexible support for housing problems
Number of subjects: 58
Study 35126208 — intervention group
Group type: COMPARATOR
Intervention: Regular housing and support services currently available (Control Group)
Number of subjects: 58
Study 35126208 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH) service
Number of subjects: 58
Study 34415475 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ablation acute surface P wave morphology and electrocardiographic parameters
Number of subjects: 160
Study 33129819 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR pullback
Number of subjects: 150
Study 33129819 — intervention group
Group type: EXPERIMENTAL
Intervention: RFR pullback
Number of subjects: 150
Study 33129819 — intervention group
Group type: EXPERIMENTAL
Intervention: dPR pullback
Number of subjects: 150
Study 33129819 — intervention group
Group type: COMPARATOR
Intervention: NHPR pullback strategy
Number of subjects: 150
Study 33270316 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic markers (F0 span, speech rate, pause proportion, jitter)
Number of subjects: 38
Study 35986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront incentive ($2)
Number of subjects: 2830
Study 35986825 — intervention group
Group type: COMPARATOR
Intervention: Response-based incentive ($10 conditional)
Number of subjects: 2830
Study 34871061 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-hour high-sensitivity troponin T protocol
Number of subjects: 0
Study 34871061 — intervention group
Group type: COMPARATOR
Intervention: masked 0/3-hour high-sensitivity troponin T protocol
Number of subjects: 0
Study 35992204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 9
Study 35992204 — intervention group
Group type: COMPARATOR
Intervention: Physician adjustment (Control)
Number of subjects: 9
Study 32351118 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVN-G3031
Number of subjects: 0
Study 35972165 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 8-mg dexamethasone
Number of subjects: 600
Study 35972165 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl as control
Number of subjects: 600
Study 36050610 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 130
Study 36050610 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 130
Study 34419100 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced observers (medical students)
Number of subjects: 4
Study 32933332 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 12
Study 32933332 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 12
Study 32933332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35106935 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 838
Study 35106935 — intervention group
Group type: COMPARATOR
Intervention: Control (no ICD)
Number of subjects: 838
Study 35106935 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary atherosclerosis presence
Number of subjects: 838
Study 32592218 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 15
Study 32592218 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical cross-trainer
Number of subjects: 15
Study 32592218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Number of subjects: 15
Study 32592218 — intervention group
Group type: COMPARATOR
Intervention: Arm ergometer
Number of subjects: 15
Study 32506738 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 100 mg
Number of subjects: 52
Study 32506738 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 1200 mg
Number of subjects: 52
Study 32506738 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52
Study 32506738 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (both doses)
Number of subjects: 52
Study 34802065 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 70
Study 34802065 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP+LCKD
Number of subjects: 70
Study 32517564 — intervention group
Group type: EXPERIMENTAL
Intervention: Rape myth intervention (treatment group)
Number of subjects: 137
Study 32517564 — intervention group
Group type: COMPARATOR
Intervention: Unrelated video content (control group)
Number of subjects: 137
Study 34814766 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment during chemotherapy
Number of subjects: 20
Study 34814766 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 20
Study 36574401 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological rehabilitation program
Number of subjects: 109
Study 33194212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic cluster randomized trials in hemodialysis
Number of subjects: 19
Study 36054921 — intervention group
Group type: COMPARATOR
Intervention: Daridorexant (exact dosage and duration not specified)
Number of subjects: 602
Study 32993544 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Feeding Genogram delivered to the intervention group (n=50)
Number of subjects: 103
Study 32993544 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Feeding Genogram
Number of subjects: 103
Study 34908223 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 1517
Study 34908223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1517
Study 32783799 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobials (azithromycin and nitazoxanide)
Number of subjects: 0
Study 32783799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (niacin vitamer)
Number of subjects: 0
Study 32783799 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 32783799 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for low enrollment weight
Number of subjects: 0
Study 32783799 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal serious adverse events
Number of subjects: 0
Study 36273926 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 564
Study 36273926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 34082074 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prescribing portraits mailed to family physicians
Number of subjects: 5157
Study 34082074 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (no immediate intervention)
Number of subjects: 5157
Study 32028090 — intervention group
Group type: EXPERIMENTAL
Intervention: In-kind team incentives
Number of subjects: 75
Study 32028090 — intervention group
Group type: COMPARATOR
Intervention: Control group (no in-kind incentives)
Number of subjects: 75
Study 35947348 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 738
Study 35947348 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks (Q8W)
Number of subjects: 738
Study 35947348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover to guselkumab Q4W at Week 24)
Number of subjects: 738
Study 35947348 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (both Q4W and Q8W)
Number of subjects: 738
Study 33892948 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NAVA
Number of subjects: 30
Study 33892948 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of baseline NAVA
Number of subjects: 30
Study 33892948 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% of baseline NAVA
Number of subjects: 30
Study 33892948 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of baseline NAVA
Number of subjects: 30
Study 33892948 — intervention group
Group type: COMPARATOR
Intervention: Doubling PEEP
Number of subjects: 30
Study 32694216 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 33559434 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy combined with Xingnao Kaiqiao acupuncture therapy
Number of subjects: 80
Study 33559434 — intervention group
Group type: COMPARATOR
Intervention: Xingnao Kaiqiao acupuncture therapy
Number of subjects: 80